<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">04631</article-id><article-id pub-id-type="doi">10.7554/eLife.04631</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology</subject></subj-group></article-categories><title-group><article-title>Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-18599"><name><surname>Fu</surname><given-names>Wenxian</given-names></name><aff><addr-line><named-content content-type="department">Department of Pediatrics</named-content></addr-line>, <institution>University of California, San Diego</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18601"><name><surname>Farache</surname><given-names>Julia</given-names></name><aff><addr-line><named-content content-type="department">Department of Microbiology and Immunobiology</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18602"><name><surname>Clardy</surname><given-names>Susan M</given-names></name><aff><addr-line><named-content content-type="department">Center for Systems Biology</named-content></addr-line>, <institution>Massachusetts General Hospital, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18603"><name><surname>Hattori</surname><given-names>Kimie</given-names></name><aff><addr-line><named-content content-type="department">Department of Microbiology and Immunobiology</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18604"><name><surname>Mander</surname><given-names>Palwinder</given-names></name><aff><addr-line><named-content content-type="department">Epinova DPU, Immuno-Inflammation Therapy Area, Medicines Research Centre</named-content></addr-line>, <institution>GlaxoSmithKline</institution>, <addr-line><named-content content-type="city">Stevenage</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-18605"><name><surname>Lee</surname><given-names>Kevin</given-names></name><aff><addr-line><named-content content-type="department">Rare Disease Research Unit</named-content></addr-line>, <institution>Pfizer</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-18606"><name><surname>Rioja</surname><given-names>Inmaculada</given-names></name><aff><addr-line><named-content content-type="department">Epinova DPU, Immuno-Inflammation Therapy Area, Medicines Research Centre</named-content></addr-line>, <institution>GlaxoSmithKline</institution>, <addr-line><named-content content-type="city">Stevenage</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-18607"><name><surname>Weissleder</surname><given-names>Ralph</given-names></name><aff><addr-line><named-content content-type="department">Center for Systems Biology</named-content></addr-line>, <institution>Massachusetts General Hospital, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18608"><name><surname>Prinjha</surname><given-names>Rab K</given-names></name><aff><addr-line><named-content content-type="department">Epinova DPU, Immuno-Inflammation Therapy Area, Medicines Research Centre</named-content></addr-line>, <institution>GlaxoSmithKline</institution>, <addr-line><named-content content-type="city">Stevenage</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-15930"><name><surname>Benoist</surname><given-names>Christophe</given-names></name><aff><addr-line><named-content content-type="department">Department of Microbiology and Immunobiology</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1136"><name><surname>Mathis</surname><given-names>Diane</given-names></name><aff><addr-line><named-content content-type="department">Department of Microbiology and Immunobiology</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country><email>diane_mathis@hms.harvard.edu</email></aff><xref ref-type="fn" rid="conf6"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1178"><name><surname>Sakaguchi</surname><given-names>Shimon</given-names></name><role>Reviewing editor</role><aff><institution>Osaka University</institution>, <country>Japan</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>11</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e04631</elocation-id><supplementary-material><ext-link xlink:href="elife-04631-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>05</day><month>09</month><year>2014</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014, Fu et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Fu et al</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Epigenetic modifiers are an emerging class of anti-tumor drugs, potent in multiple cancer contexts. Their effect on spontaneously developing autoimmune diseases has been little explored. We report that a short treatment with I-BET151, a small-molecule inhibitor of a family of bromodomain-containing transcriptional regulators, irreversibly suppressed development of type-1 diabetes in NOD mice. The inhibitor could prevent or clear insulitis, but had minimal influence on the transcriptomes of infiltrating and circulating T cells. Rather, it induced pancreatic macrophages to adopt an anti-inflammatory phenotype, impacting the NF-κB pathway in particular. I-BET151 also elicited regeneration of islet β-cells, inducing proliferation and expression of genes encoding transcription factors key to β-cell differentiation/function. The effect on β cells did not require T cell infiltration of the islets. Thus, treatment with I-BET151 achieves a 'combination therapy,' currently advocated by many diabetes investigators, operating by a novel mechanism that coincidentally dampens islet inflammation and enhances β-cell regeneration.</p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>autoimmune diabetes</kwd><kwd>bromodomain inhibitor</kwd><kwd>NF-KB</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Palwinder Mander, GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors.</p></fn><fn fn-type="conflict" id="conf3"><p>Kevin Lee, GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors.</p></fn><fn fn-type="conflict" id="conf4"><p>Inmaculada Rioja, GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors..</p></fn><fn fn-type="conflict" id="conf5"><p>Rab K Prinjha, GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors.</p></fn><fn fn-type="conflict" id="conf6"><p>Diane Mathis, Reviewing editor, eLife.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: NOD/Lt mice were bred under specific-pathogen-free conditions in our animal facility at the New Research Building of Harvard Medical School, cared for in accordance with the ethical guidelines of the Institutional Animal Care and Use Committee (#02954). Relevant studies were also conducted in accordance with GSK's Policy on the Care, Welfare and Treatment of Laboratory Animals. NOD.Cg-Rag1&lt;tm1mom&gt; mice were maintained in our lab's colony at Jackson Laboratory.</p></fn></fn-group></back></article>